key: cord-0711417-yls8nmfp
authors: Swain, Shasank S.; Singh, Satya R.; Sahoo, Alaka; Hussain, Tahziba; Pati, Sanghamitra
title: Anti-HIV-drug and phyto-flavonoid combination against SARS-CoV-2: a molecular docking-simulation base assessment
date: 2021-02-15
journal: Journal of biomolecular structure & dynamics
DOI: 10.1080/07391102.2021.1885495
sha: 6bfeaaf5c32af5cabf9c57ca99e520d85dc3d667
doc_id: 711417
cord_uid: yls8nmfp

At the health emergence, no such potent prophylactic therapy is available to control the deadly emerged Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). However, existing antiviral, anti-inflammatory, antimalarial drugs is the only option against SARS-CoV-2, but it may be harmful to patients without more clinical evidence. As an alternative solution, we proposed a newer hypothesis using the selective 10 potent anti-HIV drugs and flavonoid class of phytochemicals from previous reports to use in combination against SARS-CoV-2. Primarily, 10 anti-HIV protease inhibitor drugs and 10 phyto-flavonoids as ligands in molecular docking study against the putative target, the SARS-CoV-2-main protease (M(pro)) ID: 6Y2E), as an essential enzyme in viral genome replication. According to molecular docking and drug-ability scores of each ligand, the anti-HIV drug, the darunavir (with a docking score, −10.25 kcal/mol and drug-likeness rating, 0.60) and the quercetin-3-rhamnoside (with a docking score, −10.90 kcal/mol and drug-likeness rating, 0.82) were selected for further analysis in combined effect. Perceptibly, the combined ‘anti-HIV drug and phyto-flavonoid’ docking complex has actively interacted with eight strong H-bonds with stability, briefly elucidated through RMRD-, RMSF- Rg-plots and MM/PBSA-binding energy calculation during 100 ns than the individual against SARS-CoV-2-M(pro). Thus, the ‘anti-HIV-drug-phyto-flavonoid’ combination therapy could be used against SARS-CoV-2 after some experimental validation. Communicated by Ramaswamy H. Sarma

The pandemic of coronavirus-2019 (COVID-19) disease from the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has created a health emergency from the end of 2019 (Munster et al., 2020; Wang, Horby et al., 2020a; WHO, 2020) . The outbreak and quick transmission of the COVID-19 is close to the severe pandemic like Spanish flu in 1918-1919. However, > 78-85% of SARS-CoV-2 infected patients were found asymptomatic (Pan et al., 2020) . On the other hand, the discriminating graph of infection, genomic diversity and mortality cases from different geographical areas/communities are still unclear. As per the source, severe pneumonia and multiorgan dysfunction have been associated with a higher mortality rate from SARS-CoV-2 in different age groups (Huang et al., 2020; Islam, Ahmed et al., 2020a; Lin et al., 2020) . With the unavailability of any recommended-cum-potential drug or vaccine against the deadly disease, a considerable challenge is going on for every nation-state and the World Health Organization (WHO) to control the global health system from the unknown viral infection (WHO-Health systems respond to COVID-19, 2020 ).

According to current reports from the WHO, several existing drugs have been approved for human trials and in parallel several vaccine candidates also got permission for human testing (Caly et al., 2020; Sanders et al., 2020; Thanh Le et al., 2020) . However, fighting against the aggressive positivesense single-strand RNA or (þ) ssRNA viral infection without any effective drug/vaccine has created the most unexpected global health crisis in the 21st century (Caly et al., 2020; Sanders et al., 2020) . Physicians are still using several alternative combinations of existing antiviral, antiparasitic and antiinflammatory drugs on a hit-and-trial basis to tackle the situation (Ahn et al., 2020; Iyer et al., 2020) . Mainly, existing Food and Drug Administration (FDA) approved antiviral drugs, baloxavir marboxil, darunavir, favipiravir, lopinavir, oseltamivir, remdesivir, ritonavir, etc., several immune-modulatory, antiinflammatory medications, fingolimod, sarilumab, tocilizumab, etc., and antiparasitic drug, chloroquine, hydroxychloroquine, ivermectin are using individually and/or combination against SARS-CoV-2 in repurposing approach (Ahn et al., 2020; Gautret et al., 2020; Iyer et al., 2020) . Fortunately, applied drug combinations seem good towards controlling SARS-CoV-2 from several clinical reports. As a result, several promising anti-COVID drug and vaccine candidates got the approval from Drug Controller General of India (DCGI) for more human testing, manufacturing and marketing. However, the effectivity is still unclear due to discriminate results according to geographical region and the patient to patient variation (Ahn et al., 2020; Gautret et al., 2020; Sanders et al., 2020) .

From the vaccination point of view, among all proposed >140 vaccine candidates, only 10-12 candidates showed promising results at the final stage of the clinical validation stage. However, as per the expert source, it needs a minimum of another 5-6 months for final reports, manufacture and marketing against SARS-CoV-2. Simultaneously, several alternative non-targeting treatment therapies and regimens such as nitric oxide (NO) inhalation, human natural killer (NK) cells, or innate lymphocytes, monoclonal antibody (mAb)based formulation and several active traditional regimens are under clinical validation according to the FDA guidelines (Lu, Hwang et al., 2020a; Swain, Panda et al., 2020; Zhang et al., 2020) . Therefore, we cannot switch-off the drug combinations ordinarily until the development of any substituted-recommended vaccine candidates. However, the nonstandardized recommended drug combinations without any proper clinical evidence create severe side effects unknowingly (FitzGerald, 2020; Harrison, 2020) . Thus, the development of well-tolerated treatment therapies with lesser side effects is the call of the day.

As an alternative solution, using these screened-out antioxidants, anti-inflammatory and antiviral phytochemicals, individually or in combination with any anti-viral/anti-HIV (Human Immunodeficiency Virus) medicines expected to be a prudent option to combat the SARS-CoV-2 with diminishing post-treatment side effects. From Indian ancient Ayurvedic and Traditional Chinese Medicine (TMC), several natural products/regimens have also been active against viral diseases (Luo et al., 2020; Rastogi et al., 2020; Rege and Chowdhary, 2013; Swain, Panda et al., 2020; . The SARS-CoV-2 activity of such secondary metabolites has been reported continuously from several computational and experimental studies (Aanouz et al., 2020; Islam, Parves et al., 2020b; Ul Qamar et al., 2020; Wang, Horby et al., 2020a) . The polyphenol or flavonoid class of phytochemicals is well verified and reported to have potential immunestimulant and antiviral properties (Choi et al., 2012; Huang et al., 2014; Lalani and Poh, 2020; Pasetto et al., 2014) . In parallel, some TMC regimens have already been tested and several formulations are also under clinical validation for FDA approval after a positive response at primary assessment against SARS-CoV-2 (Gentile et al., 2020; Jin et al., 2020) .

The present work hypothesized smartly with selective anti-HIV drugs and phyto-flavonoids to combat SARS-CoV-2 with an iron hand. As per the hypothesis, an advanced, costeffective and time-saving molecular-docking-simulation approach was used to evaluate the proposed combination's potency, toxicity and drug-ability. Accordingly, the crystallographic structure of the main protease (M pro , also known as 3CL pro ) was used as a drug target during the anti-SARS-CoV-2 activity validation. The viral protease is a prudent drug target, as the M pro plays a key enzyme for viral genome replication (Gentile et al., 2020; Jin et al., 2020; Khan et al., 2020; Mohammad et al., 2020; Ul Qamar et al., 2020) . Thus, this might be a novel idea in current anti-CoV drug development modules by utilizing the potent natural products along with existing anti-HIV drugs feasibly and cost-effectively in computational-intelligence platforms.

Based on previous ethnomedicinal evidence, scientific literature and drug bank information, we have selected 10 FDA approved anti-HIV protease inhibitor drugs and 10 flavonoid class of phytochemicals for drug-combination approach against SARS-CoV-2-M pro (Supporting information Figure S1 ). The anti-HIV drugs, amprenavir, ASC09 (TMC310911), atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir and the phyto-flavonoid, apigenin, catechin, di-hydroquercetin, epi-gallocatechin gallate, hesperidin, hesperidin, LPRP-Et-97543, quercetin, quercetin-3rhamnoside and rutin were retrieved as ligands from PubChem database (https://pubchem.ncbi.nlm.nih.gov/). Further, the three-dimensional crystal structure of the SARS-CoV-2-M pro enzyme contains 306 amino acids from protein data bank (PDB) with an ID: 6Y2E, was retrieved for use as a target in the docking-simulation study. Concomitantly, the structure-and sequence-level analysis was carried out between the SARS-CoV-2-M pro with the reported crystal structure of SARS-CoV-M pro (PDB ID: 2DUC) using tools, Clustal Omega (https://www.ebi.ac.uk/Tools/msa/clustalo/) and the protein fold recognition server, Phyre2 (http://www. sbg.bio.ic.ac.uk/phyre2/).

We have used AutoDock 4.1 for molecular docking studies and the BIOVIA Discovery Studio (BIOVIA DSB v4.5) for target-ligand interaction visualization study. Saved the retrieved target structure, SARS-CoV-2-M pro and selected ligands in dot (.) pdb format before single-and double-blind docking study (Aanouz et al., 2020; Mishra et al., 2019; Swain et al., 2018; Swain, Paidesetty et al. 2020) . Then, the energy minimized structure of the SARS-CoV-2-M pro was produced through simulation at 100 nanoseconds (ns) and cleaned the geometry of each ligand to get reliability-cum-stability of the docking complexes. A default AutoDock parameter as Kollman charges-polar hydrogen bonds for the target protein and Geister partial charges-polar hydrogen for ligands were added before the docking study. Then, followed blind docking study for single and double docking with selected phytoflavonoids and anti-HIV drugs (Swain et al., 2018; Swain, Paidesetty et al. 2020) . Out of generated 10 interaction poses for each ligand, the most effective pose was selected based on its binding energy/docking score (Aanouz et al., 2020; Mishra et al., 2019; Swain, Paidesetty et al., 2020) . Notably, the inter-changeable double docking study between most potential phyto-flavonoids, quercetin-3-rhamnoside and LPRP-Et-97543 were re-docked against SARS-CoV-2-M pro -darunavir and SARS-CoV-2-M pro -tipranavir complexes, individually. Additionally, a ligand-ligand docking study was performed between darunavir-quercetin-3-rhamnoside, darunavir-LPRP-Et-97543, tipranavir-quercetin-3-rhamnoside and tipranavir-LPRP-Et-97543 (Aanouz et al., 2020; Mishra et al., 2019; Swain, Paidesetty et al., 2020) . Finally, the most effective protein with double ligand docking complexes was selected for a molecular dynamic (MD) simulation study to explore the solidity of protein-ligand binding.

The native/apo-enzyme SARS-CoV-2-M pro structure before docking, two single docking and double ligand docking complexes were selected for MD-simulation with the software GROMACS 5.1.4 (Groningen Machine for Chemical Simulations) in the GROMOS force field for 100 ns (Aanouz et al., 2020; Swain, Paidesetty et al., 2020) . Parameters and topologies files for each ligand were generated using the PRODRG server (http://prodrg1.dyndns.org/submit.html). Native protein and selected three most effective docking complexes with the SPC-E water-cubic box model (whose volume was about 976.40, 976.50, 977.48, 977.48 nm 3 , respectively) were simulated. A total of 30,576, 30,564, 30,573 and 30,563 numbers of solvent molecules were added to each system from native protein structure to double docking complexes. Neutralized the system by adding four Na þ ions and the energy minimization using 50,000 steepest descent steps, was carried out for each docking complex. After minimizing the system, the NVT (number of particles, volume and temperature) and NPT (number of particles, pressure, temperature) equilibrations were performed for equilibrating the system for the 100 ps time scale for each. The final MD step was performed for the protein system for a 100 ns time scale (Aanouz et al., 2020; Swain, Paidesetty et al., 2020).

The binding free energy calculation is another advanced computational analysis to understand the contribution of each amino acid's binding energy and dynamic behaviors in the individual protein-ligand complex (Wang, 2020; Aanouz et al., 2020; Swain et al., 2018; Wang et al., 2019) . The Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/ PBSA) based binding free energy (DG bind ) of each simulated docking complexes was calculated with the g_mmpbsav5.12 package in the GROMACS platform (Swain et al., 2018; Swain, Paidesetty et al. 2020) . The Gibb's binding free energy (DG bind ) was calculated using the following equations:

where DG is the free energy and DG complex , DG protein and DG ligand define the total free energy of an individual and the protein-ligand docking complexes in the solvent. TDS is the entropic contribution to the free energy in a vacuum where T and S represent the temperature and entropy. DG solv is the free energy of solvation, where G polar and G nonpolar are the electrostatic and nonelectrostatic contributions to the solvation free energy. DE MM is the vacuum potential energy of both bonded as well as nonbonded interactions.

The possible toxicity profiles of anti-HIV drugs and phyto-flavonoids using the generated simplified molecular-input lineentry system (SMILES) code for each chemical structure were investigated (Swain et al., 2017; Swain, Paidesetty et al. 2020 ). The toxicity profiles include hepatotoxicity, carcinogenicity, immunotoxicity, mutagenicity, cytotoxicity, toxicity class and possible lethal dose (LD 50 ) value using the tool, ProTox (http://tox.charite.de/protox_II/) was recorded for each candidate. Furthermore, the overall drug-likeness or possible drug-ability score for each ligand/candidate was measured using the tool, Molsoft (http://molsoft.com/ mprop/).

In addition to pharmacokinetics profile also play a crucial role in drug dose recommendation at a late clinical trial stage. Thus, the possible pharmacokinetic profiles such as Absorption, Distribution, Metabolism, Excretion and Toxicity (ADME/T) for all anti-HIV drugs and phyto-flavonoids were recorded using the tool, SwissADME (http://www.swissadme. ch/).

The physicochemical properties such as molecular weight (g/ mol), number of H-bond acceptors, H-bond donors, octanol/ water partition coefficient (XlogP), topological polar surface area (tPSA in Å), molar refractivity (mol/m 3 ), number of rotatable bonds of all anti-HIV drugs and phyto-flavonoids with PubChem IDs were recorded (Supporting information Tables S1 and S2). In current drug development modules, cited physicochemical parameters are collectively known as the Lipinski rule five (RO5), a standard practice to select the possible drug-able candidate in the early stage. However, all anti-HIV drugs do not follow the standard RO5 regulations, while a maximum number of phytoflavonoids follow the RO5 rules. Nevertheless, there is a mutual negotiation in both biological activity and physicochemical property during best drug selection. Simultaneously, fold recognition analysis with the selected target SARS-CoV-2-M pro (ID: 6Y2E) confirmed that a > 92% structural similarity was found with previously recognized SARS-CoV-M pro (2DUC) protein (Supporting information Figure S2 ). Concomitantly, from sequence-level analysis, 12 substituted amino acids were found, from which nine variations/mutations were conservative in between both CoV-M pro . Thus, the pandemic SARS-CoV-2-M pro is structurally conserved with previously reported SARS-CoV-M pro . The mutated amino acids may be associated with the development of severe pathogenesis and resistance to applied therapy compared to previous CoV-strain.

Since the last decade, a continuous outbreak starting from Dengue, Nipah, Ebola, Chikungunya, Zika and currently the SARS-CoV-2, an updated version of Middle East Respiratory Syndrome (MERS) and SARS from CoV family, threatening the human health and economy (Islam, Ahmed et al., 2020a; Wang, Li et al., 2020b) . Like a higher generation of drug/antibiotic, the virus also reconstructed its genome through genetic or environmental pressure; as a result, the omnipotent human unable to protect from the massive storm of deadly SARS-CoV-2 infection at present (Huang et al., 2020; Islam, Ahmed et al., 2020a; Munster et al., 2020) . The origin of SARS-CoV-2 is under investigation but it continues the unpredictable morbidity and mortality rates in wildfire gestures without any differentiation between age group, gender, race, poor, rich and geographical region (Islam, Ahmed et al., 2020a; Munster et al., 2020) .

However, the actual activities, route of transmission and especially symptoms of SARS-CoV-2 infection are still indistinguishable. Notably, the updated genomic information of SARS-CoV-2 is quite diversified from the previously isolated strain of the Co-V family; as a result, several newer serotypes continuously isolated from several geographic regions (Huang et al., 2020; Islam, Ahmed et al., 2020a; Lu, Zhao et al., 2020b; Naqvi et al., 2020; Wang, Horby et al., 2020a) . For example, in late December 2020, a newer UK-based SARS-CoV-2 genetic variant (B.1.1.7) was identified. Nevertheless, it does not seem to make more ill or increase mortality risk, but more contagious/transmissible than the previous SARS-CoV-2 (Lauring and Hodcroft, 2021) . The continuation in genomic information, clinical evidence and epidemiology analysis is stretching the scientific community in the form of prior background knowledge to develop potential therapeutic/vaccine candidates against SARS-CoV-2 (Lu, Hwang et al., 2020a; Lu, Zhao et al., 2020b; Wang, Li et al., 2020b; Wang, Zhang et al., 2020c) .

The molecular docking score of selected 20 ligands (10 anti-HIV drugs and 10 phyto-flavonoids) against the energy minimized (by 100 ns MD simulation) against the allosteric target, SARS-CoV-2-M pro were recorded (Tables 1 and 2; Figures  1-3) . Among all anti-HIV drugs, darunavir with docking score, À10.25 kcal/mol and tipranavir with docking score, À10.14 kcal/mol were the two most potential re-purposing drugs against SARS-CoV-2-M pro according to recorded docking scores (Table 1) . Similarly, from the phyto-flavonoid side, quercetin-3-rhamnoside with docking score, À10.90 kcal/mol and LPRP-Et-97543 with docking score, À10.11 kcal/mol were recorded as most potential candidates (Table 2) . From molecular interactions of docking complexes, the potent antiviral drug, darunavir formed three H-bond interactions with amino acid, LYS5 and LEU282 (Figure 3 ) and the potent phyto-flavonoid, quercetin-3-rhamnoside interacted with eight potent H-bond interactions with amino acid, LYS5, ALA7, GLN127, LYS137 and GLU290 (Figure 4 ) against SARS-CoV-2-M pro were recorded. Thus, the phyto-flavonoid quercetin-3-rhamnoside was established as a more potent and stable interaction than anti-HIV drugs. As per the hypothesis of the combination drug approach, a total of four candidates (n ¼ 4), from which two potent anti-HIV drugs, darunavir and tipranavir (n ¼ 2) and phyto-flavonoids, LPRP-Et-97543 and quercetin-3-rhamnoside (n ¼ 2) were selected (Supporting information Figure S1 ). Hypothetically, the double-docking score is comparatively higher than the individual ligand docking score. Among four double-docking complexes, the darunavir-quercetin-3-rhamnoside (n ¼ 1) combination was the most effective combination with a total docking score, À14.83 (double docking score, À10.95 kcal/mol and ligand-ligand docking score, À3.88 kcal/mol) than other double docking complexes (Table 3 ; Figure 3 ). Finally, from the above docking study, three docking complexes, SARS-CoV-2-M prodarunavir, SARS-CoV-2-M pro -quercetin-3-rhamnoside and SARS-CoV-2-M pro -darunavir-quercetin-3-rhamnoside, were selected for interaction stability analyses with MDS at 100 ns.

Currently, the computer-aided drug development (CADD) program is a cost-effective/resource-saving and a preliminary decisive method in the ongoing drug discovery module. Mainly, the high-throughput computational screening to locate active most chemical moieties based on binding energy or docking scores before synthesis and expensive experimental validation are directly influencing the reduction of cost of medicine in the later stage (Swain, Paidesetty et al., 2020; Ul Qamar et al., 2020) . Thus, the CADD program could be a promising endeavor in newer anti-CoV drug development using lead-drug candidates than the traditional hit-and-trial selection process (Hughes et al., 2011; Swain, Paidesetty et al., 2020; Ul Qamar et al., 2020) .

Towards understanding the structural stability of native protein with protein-ligand docking complexes through the root mean square deviation (RMSD)-protein backbone, root mean square fluctuation (RMSF)-C-alpha and Radius of gyration (Rg) of protein were analyzed by MD-simulation. The elucidated RMSD plot of a single protein determined that continuous unorthodoxy in backbone protein has appeared during 100 ns time. Mainly after 45 ns, found mere stability from the analyzed RMSD-plots (Figure 4) . Similarly, the RMSF- plot describes the c-alpha and Rg-plot of the whole protein, including c-alpha, backbone and side-chain described the inconsistency to maintain the stability during 100 ns in extracted plots (Figures 5 and 6) .

From the single docking complex of SARS-CoV-2-M pro -darunavir, SARS-CoV-2-M pro -quercetin-3-rhamnoside, the RMSD plot of quercetin-3-rhamnoside was comparatively more stable than the darunavir docking complex (Figure 4) . The protein backbone of SARS-CoV-2-M pro -quercetin-3-rhamnoside (green color bar in Figure 4) shows the least deviation throughout the 100 ns simulation period. In comparison, SARS-CoV-2-M prodarunavir (red color bar in Figure 4 ) displayed the variation for the first 45 ns and the rest 55 ns gradually less fluctuated in plotted RMSD. Similarly, the RMSD plot in the double docking case had comparatively higher fluctuation at an upper length, >0.4 nm between 60 and 85 ns (orange color bar in Figure 4 ). From the above RMSD plot analysis, quercetin-3-rhamnoside having the least fluctuation within 100 ns ( Figure  4) . Correspondingly, we have collected individual RMSF-and Rg-plots by overlaying plots and presented the variation with simulation time between three docking complexes ( Figures 5  and 6) . Briefly, the docking score in RMSF contest between individual quercetin-3-rhamnoside and darunavir complexes, a higher binding affinity with less fluctuation of c-alpha residues than darunavir complex was observed. Additionally, in the double docking complex, the higher in docking score than the individual with a moderate RMSF-fluctuation as the stabilization level was marked between each phyto-and anti-HIV drug. Thus, the potential quercetin-3-rhamnoside enhanced the anti-SARS-CoV-2 potency and maintained the stabilization phase in the double docking complex with darunavir ( Figure  5 ). Based on the RMSF-analyses, both anti-HIV drug and double docking complex (SARS-CoV-2-M pro -darunavir-quercetin-3rhamnoside) exhibited the most diverged value in corresponding to C-alpha residues than phyto-flavonoids. Furthermore, Rg-plots showed the compactness or solidity of the quercetin-3-rhamnoside with more squeezed Rg-values than other complexes ( Figure 6) . Additionally, H-bond interaction analyses exposed that 8 and 10 strong H-bond interactions in both SARS-CoV-2-M pro -quercetin-3-rhamnoside (green color bar in Figure 7 ) and SARS-CoV-2-M pro -darunavir-quercetin-3-rhamnoside (in the orange color bar) were found after 100 ns MD simulation (Figure 7) . Thus, in the form of activity based on strong H-bond interactions points of view, the quercetin-3-rhamnoside was a most active component than the anti-HIV drug darunavir; as a result, the flavonoid combined drug formulation exhibited the more therapeutic potency against SARS-CoV-2.

The advanced MM/PBSA calculation was performed for the above simulated three docking complexes to measure the binding energy. Before calculating the binding affinity between protein--ligand docking complexes, other energy components (E, MM, G polar and G nonpolar) between 90 and 100 ns at a 0.1 ns time step were calculated. Among all complexes, the SARS-CoV-2-M pro -darunavir-quercetin-3-rhamnoside showed the least binding energy that is À117.526 kJ/mol and the rest two complexes SARS-CoV-2-M pro -quercetin-3-rhamnoside and SARS-CoV-2-M pro -darunavir computed binding energies were À109.357 and À82.774 kJ/ mol, respectively (Table 4) . Along with binding energy, the van der Wall energy, electrostatic energy, polar solvation energy, SASA energy were also calculated for each complex, and mainly ! À0.5 kJ/mol consumed energy taken into account with a bar diagram arrangement for both individual and double docking complexes (Figure 8 ). Some common residues, such as MET6, GLU14, etc., were presented in all docking complexes. Furthermore, the backbone RMSDs, Ca-RMSF, Rg-plot, Hbond-intermolecular analyses by all-atom MD-simulation and MM/PBSA binding energy calculation provide more productive results, static thermodynamic features and underlying kinetics behavior of protein-ligand docking complexes (Swain et al., 2018; Swain, Paidesetty et al. 2020; Ul Qamar et al., 2020; Wang et al., 2019) . Notably, MD simulation suggested that SARS-CoV-2-M pro -quercetin-3-rhamnoside is the 'most-active-cum-reliable' complex than SARS-CoV-2-M prodarunavir as per the variability observation within 100 ns. Additionally, the combination of darunavir-quercetin-3-rhamnoside makes strong interactions and possesses high binding energy against SARS-CoV-2-M pro from H-bond and MM/PBSA analyses. The MD-simulation for an extended period with these complexes may share more high-volume results on stability or structural flexibility in different time intervals. Subsequently, computational tools can predict the possible toxicity and drug-ability profile of any proposed candidates and customarily make it easy to remove the unsuitable/toxic chemicals at the primary stage (Swain, Paidesetty et al., 2020) . Thus, combined drug therapy with existing anti-HIV drugs could be an excellent and inspiring repurposing approach and the utilization of more phytochemicals in mainstream medicine to purpose an alternative treatment against SARS-CoV-2 at emergency.

The toxicity or side effect is a significant concern before the recommendation of any therapeutic agents/drugs. A maximum number of lead-drug candidates are unable to express the safety profiles for human consumption and, later on, withdraw from the clinical trial/market. Herein, from the predicted toxicity profiles, phyto-flavonoids were comparatively safer than the anti-HIV drugs (Tables 5 and 6 ). However, except for hepatotoxicity and immunotoxicity, anti-HIV drugs have a safer profile like phytochemicals. The anti-HIV drug darunavir showed a moderate carcinogenicity, immunotoxicity and mutagenicity under class-III toxicity class with severe hepatotoxicity (Table 5) . Similarly, the quercetin-3-rhamnoside was reasonably safer under toxicity class-V, as a more reliable-cum-inoffensive drug candidate (Table 6 ). Table 3 . Recorded interchanged double docking and ligand-ligand docking scores against SARS-CoV-2-M pro with selected anti-HIV drugs (n ¼ 2) and phyto-flavonoids (n ¼ 2). Concurrently, the overall drug-likeness scorers for each ligand were recorded (Tables 1 and 2). As per the drug-ability plot, a positive drug-likeness value is good; a score between 0.60 and 1.20 is a perfect score for a successive drug molecule. The recorded predicted value concluded that all anti-HIV drugs showed positive drug-likeness scores. It was discernible that all phyto-flavonoids also exhibited positive drug-like scores similar to anti-HIV medicines. Significantly, the drug-ability score of the quercetin-3-rhamnoside had the most potential score, 0.82, while the anti-HIV drug darunavir score, 0.60 (Supporting information Figures S3 and S4) . Thus, the predicted drug-likeness score evidenced and expected the success of the proposed phyto-drug combination against SARS-CoV-2.

At the later stage of drug validation, the pharmacokinetics profile plays a crucial role during dose recommendation. Moreover, advanced computational tools can provide possible statistical-based reports for each candidate from the massive amount of training set documents at an early stage.

Herein, both anti-HIV drugs and phyto-flavonoids pharmacokinetics profils were recorded (Supporting information Tables S3 and S4). As per reports, except for lopinavir and indinavir, the rest of the anti-HIV medicines have lower gastrointestinal absorption (GI-abs.), including darunavir (Supporting information Table S3 ). Similarly, all drugs are unable to cross the blood-brain barrier (BBB) report. On the other hand, pharmacokinetics profiles of phyto-flavonoids displayed in a variability manner of GI-abs, P-gp substrate, but quercetin-3rhamnoside showed a similar pharmacokinetic profile to the anti-HIV drug. Similarly, all phytochemicals showed the same negative BBB cross report (Supporting information Table S4 ). The overall pharmacokinetics report of all ligands were presented, graphically (Supporting information Figures S5 and  S6 ). The comprehensive reports showed all ligands/candidates recorded in deviate pharmacokinetics profile, mainly phytochemicals. Hopefully, the combination of the mainstream drug with phytochemicals may have enhanced the anti-SARS-CoV-2 activity and stability of the pharmacokinetics profiles in synergism during treatment.

At present, from the experience of previously used combinations against MERS-and SARS-CoV strains were more viable, as members of similar taxa with a higher genomic match ( Lu, Zhao et al., 2020b; Wang, Li et al., 2020b; Wang, Zhang et al., 2020c) . The anti-HIV drugs, ASC09, darunavir, lopinavir, ritonavir as potent viral protease inhibitors, oseltamivir, a potent anti-H1N1 neuraminidase inhibitor, favipiravir and umifenovir as potent anti-influenza drugs targeting viral RNA-dependent RNA polymerase, anti-ebola drug, remdesivir targeting viral RNA polymerase, are most widely used drugs in repurposing basis with several combinations (Harrison, 2020; Sanders et al., 2020) . However, the multidrug combinations are complicated in SARS-CoV-2 patients with multiple comorbidities such as diabetics, hypertension, respiratory disease and cardiac dysfunctions (Newman and Cragg, 2020; Tungmunnithum et al., 2018) . Similarly, several nontarget conventional treatment therapies with natural regimens/products are quite a classic for most infectious diseases (Newman and Cragg, 2020; Tungmunnithum et al., 2018) . Ordinarily, phytochemicals have been suggested as a vibrant conservative resource, since individual plant crude extracts and isolated secondary metabolites curative potential against various health ailments (Choi et al., 2012; Huang et al., 2014; Newman and Cragg, 2020; Swain, Panda et al., 2020; Tungmunnithum et al., 2018) . Natural plant products such as curcumin, quinine, taxol, vincristine, morphine, etc., have been playing a significant role in the contribution of several mainstream medicines (Choi et al., 2012; Huang et al., 2014; Newman and Cragg, 2020; Russo et al., 2010) . Indeed, from the structural point of view, the flavonoid or polyphenol class of phytochemicals is more suitable and safer secondary metabolites for human administration with potent immune-stimulant and antioxidant as a lesser toxic/nontoxic class of drug candidates (Newman and Cragg, 2020; Russo et al., 2010; Swain, Panda et al., 2020). For example, the flavonoid class of Figure 8 . Energy per residue of M pro -drug, M pro -phyto and M pro -drug-phyto docking complexes have been recorded through the MM/PBSA binding energy calculation method during 100 ns MD-simulation. Only energy ! -0.5 kJ/mol was taken into account for visualization in the above figures and displayed that the 'phytodrug' combination has a prominent contribution in the form of effectivity than the individual. derivatives, phenoxodiol, genistein and polyphenolic constituents from green tea and soyabeans, is now in a different clinical trial stage as a potent anticancer regimen (Newman and Cragg, 2020; Russo et al., 2010) . Someway, nonconventional therapy using Ayurveda and TCM regimens gives some productive outputs against SARS-CoV-2 from several recent reports ( Ali et al., 2020; Islam, Parves et al., 2020b; Luo et al., 2020; Swain, Panda et al., 2020; . Therefore, the proposed 'anti-HIV-drug-phyto-flavonoid' combination could be a potential and safer combination therapy against SARS-CoV-2. Strategically, computer-aided drug design could be a promising endeavor in newer anti-CoV drug development during possible lead-drug candidate(s) selection than the traditional hit-and-trial selection process in this challenging time.

Currently, the entire global health system is in the emergency and the whole community lives under a lack of selfconfidence from the pandemic of SARS-CoV-2. Based on previous pharmacological evidence, the repurposing of existing antiviral, antiinflammatory, antiparasitic medicines are the only therapeutic options against SARS-CoV-2. However, clinical dose and a proper assessment of posttreatment side effects of repurposing drug therapies are essential guideline- Table 5 . Computationally predicted toxicity profiles including toxicity class of anti-HIV drug based on its chemical structure, using the tool, ProTox. The green-color indicates safer and the light cyan-color indicate moderate safer chemical and on other hand, red color indicates the toxic/hazard class of chemical and light pink indicates moderate toxic in nature. cum-challenge for any physician/clinician, as treatment has been linked with severe side effects/host-toxicity from several clinical reports. As an alternative solution, we proposed a newer hypothesis using potent an active flavonoid class of phytochemicals with anti-HIV drugs towards balancing the toxicity and biological activity to combat SARS-CoV-2. In parallel, flavonoids are a potent anti-oxidant, anti-inflammatory, immune-stimulant with potent antiviral activities with nontoxic action/safer therapeutic agents for human consumption. Briefly, based on advanced molecular docking-simulation (RMSD, RMSF, Rg and H-bond integration analyses), binding energy score, drug-likeness score, toxicity and pharmacokinetic profiles, the 'darunavir-quercetin-3-rhamnoside' was the most effective and less toxic pharmacological active mishmash against SARS-CoV-2-M pro .

Moroccan medicinal plants as inhibitors of COVID-19: Computational investigations

Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19)

The outbreak of coronavirus diseases 2019 (COVID-19) -An emerging global health threat

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Quercetin 3-rhamnoside exerts antiinfluenza A virus activity in mice

Misguided drug advice for COVID-19

Hydroxy-chloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial

Putative inhibitors of SARS-CoV-2 main protease from a library of marine natural products: A virtual screening and molecular modeling study

Coronavirus puts drug repurposing on the fast track

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Anti-viral effect of a compound isolated from Liriope platyphylla against hepatitis B virus in vitro

Principles of early drug discovery

Emergence of deadly severe acute respiratory syndrome coronavirus-2 during

A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2

COVID-19: An update on diagnostic and therapeutic approaches

Structure of M pro from SARS-CoV-2 and discovery of its inhibitors

Structure-based identification of potential SARS-CoV-2 main protease inhibitors

Flavonoids as antiviral agents for Enterovirus A71 (EV-A71)

Genetic variants of SARS-CoV-2-what do they mean?

Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerging Microbes and Infections

Development of therapeutic antibodies for the treatment of diseases

Genomic characterization and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding

Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): An empirical study from Wuhan

Possible activation of NRF2 by Vitamin E/Curcumin against altered thyroid hormone induced oxidative stress via NFOEB/AKT/mTOR/KEAP1 signalling in rat heart

Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy

A novel coronavirus emerging in China -Key questions for impact assessment

Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach

Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019

Asymptomatic cases in a family cluster with SARS-CoV-2 infection

Anti-HIV-1 activity of flavonoid myricetin on HIV-1 infection in a dual-chamber in vitro model

COVID-19 Pandemic: A pragmatic plan for Ayurveda intervention

Evaluation of some medicinal plants as putative HIV-protease inhibitors

Phytochemicals in cancer prevention and therapy: Truth or dare?

Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review

Development of antibacterial conjugates using sulfamethoxazole with monocyclic terpenes: A systematic medicinal chemistry based computational approach

Computer-aided synthesis of dapsone-phytochemical conjugates against dapsone-resistant Mycobacterium leprae

Molecular docking and simulation study for synthesis of alternative dapsone derivative as a newer antileprosy drug in multidrug therapy

Phytochemicals against SARS-CoV as potential drug leads

The COVID-19 vaccine development landscape

Flavonoids and other phenolic compounds from medicinal plants for pharmaceutical and medical aspects: An overview

Structural basis of SARS-CoV-2 3CL pro and anti-COVID-19 drug discovery from medicinal plants

A novel coronavirus outbreak of global health concern

End-point binding free energy calculation with MM/PBSA and MM/GBSA: Strategies and applications in drug design

The genetic sequence, origin, and diagnosis of SARS-CoV-2

Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study

Structural and functional basis of SARS-CoV-2 entry by using Human ACE2

WHO-Health systems respond to COVID-19

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis

Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): A review and perspective

Current status of potential therapeutic candidates for the COVID-19 crisis

Authors' contributions S.S.S., S.R.S., A.S. conceptualized the research design; S.R.S., A.S, carried out the advanced computation assessments and organized the results according to S.S.S direction; S.S.S. drafted the MS and T.H. S.P. provided overall support.

No potential conflict of interest was reported by the authors.